With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according to analysts Datamonitor, the specialist biotechs Nektar, BioMarin and Alnylam are the ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR), currently trading at $0.87 with a market capitalization of $162.5 million, announced today that it has achieved target enrollment for its Phase ...